Navigation Links
Autonomy(TM) Lapro-Angle(TM) Articulating Laparoscopic Instruments Granted CE Mark
Date:8/4/2008

laparoscopic procedures currently performed in the U.S. will convert to the single port access technique due to the compelling patient benefits that it offers. With the CE Mark in place, surgeons in Europe will now be able to offer this exciting technique to their patients."

About Cambridge Endo

Cambridge Endo is a privately held medical device company that designs, develops and manufactures innovative articulating laparoscopic instruments. The Autonomy(TM) Lapro-Angle(TM) product line is an enabling technology for Single Port Access surgery. Autonomy articulating instruments are also used in many traditional laparoscopic procedures by general surgeons, bariatric surgeons, urologic surgeons, gynecologic surgeons and other surgical specialties.

Cambridge Endo is headquartered in Framingham, MA. For more information about Cambridge, please visit http://www.cambridgeendo.com.

Contact:

Woojin Lee, Ph.D.

508-405-0790

wlee@CambridgeEndo.com


'/>"/>
SOURCE Cambridge Endo
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
2. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
3. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
4. Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year
5. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
6. Nikon Instruments Launches New Eclipse Ti-E Fully-Integrated, Motorized Inverted Microscope
7. Advanced Instruments Acquires Mart Microbiology B.V.
8. Nikon Instruments Introduces NIS-Elements Software for Eclipse Ti-E Live-Cell Applications
9. Neogen Acquires Assets of Rivard Instruments
10. Nikon Instruments Partners With Koshland Science Museum to Create the Museums First-Ever Microbe Lab
11. Nikon Instruments Launches Fully-Automated A1 Confocal Laser Microscope Series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , NEW YORK, Dec. 2 Reportlin...t is available in its catalogue: ,, Carbondiox..., http://www.reportlinker.com/p0164368/Carbondiox... ,, Incubators are the most critical equipment... and other applications for providing a controlled...
(Date:12/2/2009)... , CALGARY, Dec. 2 /PRNewswire-FirstCall/ - O...ny") (TSX:ONC; NASDAQ: ONCY ) announced today that...offering, the underwriters have exercised in full ...ional 637,500 units. Each unit is comprised of one...arrant, and was sold at a price of US$3.00 per uni...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte...el oral JAK2 inhibitor, SB1518, at The American So...tion in New Orleans. ,, Data will be presented ...lation trial of SB1518 detailing its safety, toler...) profile in dose levels ranging from 100 to 600 m...
(Date:12/2/2009)... The Scientist, a leading scientific...metrics’ Evolve “Intelligent” EM...dquo;Top 10 Innovations of 2009. , ...™ EMCCD camera from Photometrics ®, a ...and EMCCD cameras for the life sciences, was ranke...
Breaking Biology Technology:Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
...s,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today an... the fiscal year and the three-month period ended ...rence call and webcast today beginning,at 9:00 am ...ompany reported fiscal 2008 consolidated revenues ...07 revenues of $66.1 million. For the three-,mont...
... Heart, Inc. is pleased to,announce the appointmen...ive,Officer (C.E.O.) and President, effective imme...Terumo Heart is positioned for a strong leadership...am excited to lead the acceleration,of enrollment ...linical sites,and further capitalize on the commer...
...c Imaging will produce its,11th Annual Webcast Fro...Radiology Society of North America Scientific Asse...L, from November 30th through December 5th. This,...ents taking place and will,be available on Diagnos...s the opportunity to join our team of editors as,t...
Other Biology Technology:Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 2Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 3Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 4Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 5Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 6Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 7Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 8Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 9Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 10Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 11Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President 2Diagnostic Imaging to Deliver Its 11th Annual Webcast of Key Events Taking Place at RSNA 2008 2
(Date:12/3/2009)...panish researchers have measured CO2 levels for th...phere) over a sparsely inhabited rural area near V...ir kind in the Iberian Peninsula, show that the le..., Over recent years, physicists and meteorologist...e (CO2) levels, and how these have evolved in the ...
(Date:12/3/2009)... 30-year record low in Antarctic snowmelt that occ... due to concurrent strong positive phases for two ...llation) and SAM (Southern Hemisphere Annular Mode...ssor of Earth & Atmospheric Sciences at The City C...s also on the doctoral faculty at the CUNY Graduat...
(Date:12/2/2009)...HILADELPHIA New study results strengthen the evid...period of time have an increased risk for developi...er risk factors. , "This provides one more reas...said senior author Michael J. Thun, M.D., M.S., vi...ce research at the American Cancer Society. "Color...
Breaking Biology News(10 mins):CO2 levels rising in troposphere over rural areas 2CCNY professor foresees rising Antarctic snowmelt 2Cigarette smoking increases colorectal cancer risk 2EntreMed Reports Second Quarter 2009 Financial Results 53818 1EntreMed Reports Second Quarter 2009 Financial Results 53818 2EntreMed Reports Second Quarter 2009 Financial Results 53818 3EntreMed Reports Second Quarter 2009 Financial Results 53818 4Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 1Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 2Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 3Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 4Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 5Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 6Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 7Celiac Disease Provides Clues To Solving Autoimmunity 53814 1Celiac Disease Provides Clues To Solving Autoimmunity 53814 2Celiac Disease Provides Clues To Solving Autoimmunity 53814 3
...y of Illinois study have demonstrated an effective...ate bars. , Eating two CocoaVia dark chocolate ba...unexpected effect of also lowering systolic blood ...f food science and human nutrition. , The study, ...s the bars, was published in this months Journal o...
...eview, scientists at Childrens Hospital & Research...ological or behavioral evidence linking vitamin D ...Ph.D., assistant staff scientist and Bruce N. Ames...kland Research Institute (CHORI) conclude that the...rtant role for vitamin D in brain development and ...
...e Multiplier for Shelbyville Police Department, W...TC Bulletin Board: BKYI), a leader in finger-based...ty solutions, today announced the,award of a contr...epartment") for the Department,s first mobile data...ireless messaging and query solution,officers on t...
Other Biology News:Chocolate bar shown to lower cholesterol 2Vitamin D in brain function 2Vitamin D in brain function 3BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency 2BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency 3
Mouse Anti-Human XPMC2H Polyclonal Antibody, Unconjugated from Novus Biologicals
BD Falcon cultivation flask from BD Biosciences - Discovery Labware
...sphere/Microarray Stabilizer is an aqueous solutio...r non-toxic chemicals in a PBS buffer (phosphate b...ns a combination of 0.02% methylisothiazolone and ...Coat Plus Stabilizer provides optimum performance ...
Mini Incubation Trays, 100 from Bio-Rad
Biology Products: